Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
TNF Pharmaceuticals, Inc. (NASDAQ:TNFA), a diagnostic substances company with a market capitalization of just $1.01 million, has been notified by the Nasdaq Stock Market that it is at risk of being delisted. The notice, dated March 17, 2025, was issued because the company’s common stock, currently trading at $0.37, had not maintained the minimum required bid price of $1.00 per share over the previous 30 consecutive business days. According to InvestingPro data, the stock has declined over 87% in the past year, though analysis suggests the company may be undervalued at current levels.
According to the Nasdaq Listing Rule 5550(a)(2), TNF Pharmaceuticals’ stock price fell short of the benchmark between January 30, 2025, and March 14, 2025. The company’s shares have shown significant volatility, with a beta of 2.53, and have fallen more than 70% in the past six months. In response, Nasdaq has granted the company a 180-day compliance period, ending on September 15, 2025, to meet the minimum bid price requirement. InvestingPro subscribers have access to 10 additional key insights about TNFA’s financial health and market performance.
To regain compliance, TNF Pharmaceuticals’ common stock must have a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days during this period. If the company fails to comply by the deadline, it may be eligible for a second 180-day period to address the price deficiency, provided it meets other initial listing standards for The Nasdaq Capital Market and submits a written notice of its intent to correct the issue, potentially through a reverse stock split.
The company’s listing on The Nasdaq Capital Market remains active for now, contingent on adherence to other listing requirements. However, if TNF Pharmaceuticals does not achieve compliance within the allotted time, and if Nasdaq determines that the company will not be able to remedy the deficiency or is ineligible for an additional compliance period, it may initiate delisting procedures. In such a case, the company would have the opportunity to appeal the decision.
This development comes amidst a series of name changes for the company, previously known as MyMD Pharmaceuticals, Inc., Akers Biosciences, Inc., and Akers Biosciences Inc, with changes occurring on April 20, 2021, April 13, 2017, and March 25, 2005, respectively. Despite trading at just 0.06 times book value and maintaining a healthy current ratio of 1.72, the company faces significant challenges. The company’s headquarters are located at 1185 Avenue of the Americas, Suite 249, New York, NY, and it is incorporated in Delaware. Get comprehensive financial analysis and real-time alerts with InvestingPro.
The information regarding TNF Pharmaceuticals’ notice of potential delisting is based on a recent SEC filing.
In other recent news, TNF Pharmaceuticals held a conference call to discuss advancements in their lead compound, Isomyosamine. The company provided updates on their research and development efforts, emphasizing that the information shared is now available in a transcript attached to a Form 8-K filed with the SEC. TNF Pharmaceuticals clarified that the details disclosed in the call are not considered "filed" for purposes of Section 18 of the Exchange Act and are not subject to its liabilities. The transcript of the conference call is publicly accessible as Exhibit 10.1 in the Form 8-K. This allows investors and interested parties to review the discussion in detail. TNF Pharmaceuticals continues to maintain its commitment to transparency and regular communication with stakeholders about its research and development activities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.